Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    NovoCure Limited

    NASDAQ: NVCR · Real-Time Price · USD
    12.43
    0.52 (4.37%)
    At close: Aug 22, 2025, 3:59 PM
    12.42
    -0.08%
    After-hours: Aug 22, 2025, 07:55 PM EDT
    4.37%
    Bid 12.32
    Market Cap 1.39B
    Revenue (ttm) 630.16M
    Net Income (ttm) -170.95M
    EPS (ttm) -1.56
    PE Ratio (ttm) -7.97
    Forward PE -7.09
    Analyst Buy
    Ask 12.46
    Volume 1,349,945
    Avg. Volume (20D) 1,694,156
    Open 12.03
    Previous Close 11.91
    Day's Range 11.96 - 12.47
    52-Week Range 10.87 - 34.13
    Beta 0.61

    About NVCR

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NVCR
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for NVCR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    NovoCure Limited is scheduled to release its earnings on Oct 29, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    4 weeks ago
    -24.05%
    NocoCure shares are trading lower. The company rep... Unlock content with Pro Subscription
    2 months ago
    -10.83%
    NovoCure shares are trading lower after the company announced its PANOVA-3 trial results.
    news image

    1 day ago · zacks.com

    NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

    NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.

    news image

    2 days ago · businesswire.com

    Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

    BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields...

    news image

    3 weeks ago · seekingalpha.com

    NovoCure's Wearable Oncology Edge And Compelling Valuation

    NVCR focuses on Tumor Treating Fields wearables for GBM, mesothelioma, and NSCLC. These are its main recurring revenue verticals. So far, its wearables have shown favorable safety profiles, and sugges...

    news image

    3 weeks ago · fool.com

    Why NovoCure Stock Is Cratering Today

    Shares of Novo Nordisk (NVO -21.28%) are plunging on Tuesday, down 21% as of 2:10 p.m. ET. The drop comes as the S&P 500 (^GSPC) and the Nasdaq Composite (^IXIC) both lost 0.3%.

    news image

    4 weeks ago · seekingalpha.com

    NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

    NovoCure Limited (NASDAQ:NVCR ) Q2 2025 Earnings Conference Call July 25, 2025 8:00 AM ET Company Participants Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leona...

    news image

    4 weeks ago · fool.com

    NovoCure Q2 Revenue Jumps 6 Percent

    NovoCure (NVCR -23.93%), the oncology device firm advancing Tumor Treating Fields therapy, released its second quarter 2025 results on July 24, 2025. GAAP revenue totaled $158.8 million in Q2 2025, an...

    news image

    1 month ago · zacks.com

    NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say

    The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate...

    news image

    4 weeks ago · fool.com

    Novocure: Steady Ahead of Key Milestones

    Here's our initial take on Novocure's (NVCR -9.99%) fiscal 2025 second-quarter financial report.

    news image

    4 weeks ago · zacks.com

    NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

    NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.31 per share a year ago.

    news image

    4 weeks ago · businesswire.com

    Novocure Reports Second Quarter 2025 Financial Results

    BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend su...

    Add to Watchlist